Mitiglinide (KAD-1229), an insulinotropic agent, is anATP-sensitive K⁺(K_ATP) channelantagonist. Mitiglinide is highly specific to the Kir6.2/SUR1 complex (the pancreatic beta-cell K_ATPchannel). Mitiglinide can be used for the research of type 2 diabetes^[1][2].

K_ATPchannel^[1]

Mitiglinide inhibits the Kir6.2/SUR1 channel currents in a dose-dependent manner (IC₅₀of 100 nM) but does not significantly inhibit either Kir6.2/SUR2A or Kir6.2/SUR2B channel currents even at high doses (more than 10 μM) in COS-1 cells^[1].

Mitiglinide (1-3 mg/kg; p.o.) suppresses the increase in plasma glucose levels seen after a meal load and the area under the curve for plasma glucose levels (AUCglucose) up to 5 h after the meal load^[2].

315.41

C₁₉H₂₅NO₃

145375-43-5

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.